How the 2026 Election Affects Home Health, Home Care, and Hospice Valuations
Updated: Nov 6
By Cory Mertz, M&AMI, Managing Partner, Mertz Taggart · November 5, 2026 ·

At a Glance Democrats won control of the House and Senate, and the new Congress takes office in January. For home health, home care, and hospice owners, that may make additional major Medicaid cuts harder to enact, but it does not reverse existing law or raise agency valuations on its own. Reimbursement, staffing, sustainable earnings, and compliance still drive value. |
How will the 2026 election affect home-based care M&A? Our expectation is continued acquisition activity, not an automatic increase in agency valuations. Divided government should make additional major Medicaid cuts harder to enact, but it does not reverse existing law. For an owner considering a sale, reimbursement, staffing, sustainable earnings, and compliance remain more useful indicators of value than the election result alone.
Democrats have won control of the House and Senate, setting up divided government when the new Congress takes office in January. President Trump remains in office. That limits how quickly, and how completely, healthcare policy can change.
The practical question is whether anything changes the earnings a buyer can reasonably expect your agency to generate, the risks attached to those earnings, or the buyers willing to compete for your business.
Our base case is less room for additional major Medicaid cuts, more healthcare oversight, and no automatic increase in home health, home care, or hospice valuations. That is our judgment, not a quantified forecast of election-driven changes in deal volume or EBITDA multiples.
Will the election increase agency valuations?
We would not assume an election-driven increase in EBITDA multiples. A more favorable policy outlook can improve confidence, but reduced concern about a future cut is not the same as an enacted reimbursement increase. Neither guarantees that your margins improve.
A buyer might become more comfortable with your reimbursement outlook without changing its assessment of your staffing costs, referral concentration, or ability to grow.
Our assessment differs by business model:
Medicaid-funded home care: We would watch state funding decisions and reimbursement relative to caregiver wages.
Medicare-certified home health: We would focus on agency-specific payment changes, payer contracts, and clinical productivity.
Hospice: We would examine the durability of earnings and clinical, documentation, and reimbursement exposure.
Private-pay home care: We would assess whether billing rates, caregiver compensation, and client retention support sustainable margins.
For transaction context rather than an election forecast, see our Q3 2026 Home-Based Care M&A Report.
How will the 2026 election affect Medicaid home care funding?
Existing funding pressure does not disappear. Another major legislative reduction in Medicaid funding becomes less likely, but a rapid reversal of existing funding restrictions is a much weaker assumption.
A Democratic Congress will have greater leverage over legislation, spending negotiations, and oversight. However, Holland & Knight’s pre-election analysis cautioned that outright repeal of provisions in the 2025 reconciliation law would be difficult. Targeted delays or additional implementation flexibility were more plausible avenues for change.
BRG’s John Barkett made the constraint clear in comments reported by Fierce Healthcare on November 2: “President Trump will still be president, and he will view a policy that amends the One Big Beautiful Bill Act in favor of hospitals as a concession to Democrats—and therefore, he’ll be looking for something in return.”
His comments concerned hospitals, not home care valuations. The relevant point for agency owners is the legislative constraint: a new congressional majority does not automatically reverse existing law.
Home care also has an influential advocate in Sen. Ron Wyden (D-OR), currently the top Democrat on the Senate Finance Committee. His October home care initiative seeks to expand access and strengthen the workforce. With Democrats taking Senate control in January, we expect that agenda to receive greater attention. That improves the prospects for hearings and targeted negotiations, not a guarantee of new funding or higher agency margins.
Exposure also remains state-specific. KFF’s October analysis of Medicaid home care noted that most services are optional for states to provide and could face pressure from reduced federal funding. Some states had cut programs, while others continued making enhancements.
For your agency, we would focus on whether reimbursement can keep pace with caregiver compensation, whether authorized hours become delivered and billable hours, and how much of your earnings depends on a rate increase or program decision that may not be sustainable.
Those answers are more useful in a valuation discussion than a national election headline.
What does the election mean for home health reimbursement?
CMS finalized the 2027 home health rule on November 4, 2026, estimating a 2.4% aggregate increase in Medicare payments over 2026. That is an industry-wide estimate, not a forecast for your agency. For what the final rule means for values, see 2027 Home Health Final Rule: What It Means for Agency Values and M&A.
We would assess a sale using the final payment rule and your actual economics, rather than assuming congressional control will deliver a particular reimbursement result.
There is bipartisan support for protecting home health access. Reps. Kevin Hern (R-OK) and Terri Sewell (D-AL) introduced the Home Health Stabilization Act in 2025 to pause payment reductions while a more sustainable system is developed. We see targeted reimbursement relief as a more plausible policy outcome than an election-driven valuation premium. But an owner should not count that relief as earnings until the applicable policy actually changes.
The operating constraints predate this election. In its 2024 skilled home healthcare outlook, Marwood Group identified aging demographics as a demand driver while highlighting staffing shortages as a challenge to serving that demand.
Our view is that favorable demand has limited transaction value if your agency cannot staff admissions profitably. Demonstrating referral conversion, clinician capacity, and payer-level profitability is more productive than waiting for a political benefit.
How does the election affect hospice payments and oversight?
It does not change them directly. Hospice’s fiscal 2027 Medicare payment update was established before the election. CMS set a 2.3% increase, effective October 1, 2026, subject to applicable adjustments and quality-reporting requirements.
That rule also highlighted claims-based information intended to identify providers that may need additional education and oversight. The election did not create the payment update or remove the compliance focus.
Hospice advocates are not proposing less oversight across the board. Sen. Mark Warner (D-VA) and Rep. Linda Sánchez (D-CA) introduced the Hospice CARE Act in March 2026 with proposed home respite benefits and payment reforms alongside stronger ownership transparency and more surveys. Our takeaway: support for the hospice benefit can mean expanded services and tighter accountability at the same time, not an automatic improvement in every operator’s economics.
We do not expect the result to eliminate the investment case for a well-run hospice. Nor do we expect it to make unresolved compliance exposure easier to sell.
Our approach would remain the same: establish sustainable earnings, examine patient eligibility and documentation, understand aggregate cap exposure, and resolve issues that could cause a buyer to question the business.
Should private-pay home care owners count on labor-rule savings?
Not as current earnings. Private-pay home care owners should separate federal reimbursement policy from their own business economics.
Labor policy remains relevant. The Department of Labor has proposed restoring broader companionship and live-in domestic service exemptions. Its published guidance describes a proposal, not a blanket, finalized exemption for home care agencies.
We would not count uncertain regulatory savings as current EBITDA. Even if an exemption becomes available, your agency still needs to recruit and retain caregivers, comply with applicable requirements, and maintain service quality.
For a sale, distinguish demonstrated margins from potential upside dependent on a future policy change.
Can home health and hospice acquisitions still close?
Yes. The Medicare enrollment moratorium is not a blanket acquisition ban.
CMS’s guidance allows enrolled providers to acquire or merge with other enrolled providers when the transaction does not require a new enrollment under applicable ownership-change rules and does not add new locations. Existing certified locations transferred through a qualifying transaction are not treated as new locations.
CMS imposed the six-month nationwide moratorium beginning May 13, 2026, with the possibility of extensions.
For your transaction, ownership history and enrollment requirements may matter more than the election result. Verify those facts early. Do not assume either that a sale is blocked or that an existing enrollment automatically commands a premium.
Policy status as of November 2026
Policy | Status |
Home health CY2027 payment rule | Final, Nov. 4, 2026; est. +2.4% aggregate |
Hospice FY2027 payment update | Final; +2.3%, effective Oct. 1, 2026 |
HH/hospice enrollment moratorium | Six months from May 13, 2026; may be extended |
DOL companionship/live-in exemption | Proposed, not final |
Home Health Stabilization Act | Introduced 2025 |
Hospice CARE Act | Introduced March 2026 |
Should you sell your agency now or wait?
We would not change sale timing solely because of the election.
Waiting can make sense when a specific, achievable improvement could materially strengthen earnings or reduce buyer risk. Examples include stabilizing staffing, demonstrating the benefit of an implemented rate increase, improving payer contracts, or resolving a compliance issue.
Waiting for a broadly “better political environment” is a less defensible plan. It has no defined outcome or timetable.
For a sale over the next 12–24 months, we would assess:
What your agency can sustainably earn under applicable rules.
Which buyers have a credible reason to acquire it.
What could materially change earnings or buyer interest before a sale.
Whether the expected benefit of waiting justifies the operating and personal risk.
Our expectation is continued, selective acquisition activity, not an election-driven surge or a broad withdrawal of buyers. The useful response is to understand your agency’s specific exposure and make the decision around your business and your objectives.
For more on preparation, read Selling a Home Health, Hospice, or Home Care Agency in 2026.
Frequently asked questions
Does a change in Congress automatically change Medicare reimbursement?
No. A change in congressional control does not itself change your agency’s Medicare payment rates. Congress can change the law and oversee agencies, but payment outcomes depend on the applicable legislation and CMS rules. Do not model an election result as an enacted rate increase.
Will Medicaid funding pressure affect private-pay home care the same way?
Not directly. A private-pay agency’s revenue is not funded through Medicaid reimbursement. We would examine its actual payer mix, caregiver costs, and clients’ ability to afford services rather than apply a Medicaid funding assumption to the entire business.
Does the election lift home health and hospice enrollment restrictions?
No. The election itself does not lift CMS’s enrollment moratorium. Whether a transaction can proceed depends on the applicable requirements, including whether it requires a new enrollment. Check current CMS guidance and the agency’s ownership history before choosing a transaction structure.
Key Takeaways
|
Considering a sale? If you want to understand how reimbursement, staffing, or policy exposure could affect your agency’s value, contact Mertz Taggart for a confidential conversation.
Cory Mertz, M&AMI, is Managing Partner at Mertz Taggart, where he advises home health, home care, and hospice owners on selling their businesses.
Policy status reviewed November 6, 2026. Expectations about valuations and acquisition activity reflect Mertz Taggart’s judgment, not a guarantee of transaction outcomes.

Comments